Is dual antiplatelet therapy beneficial for post-CABG diabetes patients?
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Routine dual antiplatelet therapy (DAPT) may not be clinically warranted in diabetes patients with multivessel disease undergoing coronary artery bypass grafting (CABG).
Why this matters
Diabetes is independently associated with increased perioperative and long-term mortality in CABG patients.
Post-hoc, nonrandomized analysis from FREEDOM (Future REvascularization Evaluation in patients with diabetes mellitus: Optimal management of Multivessel disease) trial, comparing 544 patients receiving DAPT (aspirin+thienopyridine) with 251 on aspirin monotherapy at 30 days post-operatively.
No significant differences in 5-year primary composite outcome of all-cause death, myocardial infarction, or stroke (12.5% vs. 16.0%, adjusted hazard ratio [HR] 0.83, p=.39).
No significant differences in secondary outcomes of all-caus...